Tocilizumab – interleukin 6 receptor inhibitor – a new therapeutic option in the treatment of rheumatoid arthritis

Interleukin 6 is a pleiotropic cytokine which regulates the innate and adaptive immune response, inflammation and acute phase response. It plays a significant role in various chronic inflammatory processes including rheumatoid arthritis. The inhibition of IL-6 signal transduction by monoclonal antibodies against IL-6 receptor is a new efficient and safe therapeutic method in rheumatoid arthritis

REFERENCES (17)

Naka T, Nishimoto N, Koshimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002; 4 Suppl 3: S233-S242. .

Google Scholar

Jones SA, Richards PJ, Scheller J, et al. IL-6 trans-signalling: the in vivo consequences. J Interferon Cytokine Res 2005; 25: 241-253. .

Google Scholar

Rich RR. Clinical Immunology. 2nd ed. Mosby, Elsevier 2008. .

Google Scholar

Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006; 8 (Suppl): S3. .

Google Scholar

Choy E. Interleukin 6 receptor as a target for the treatment of rheumatoid arthritis. Ann Rheum Dis 2003; 62 (Suppl II): ii68-ii69. .

Google Scholar

Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T (H) 17 cells. Nature 2008; 453: 1051-1057. .

Google Scholar

Adachi Y, Yoshio-Hoshino N, Nishimoto N. The blockade of IL-6 signaling in rational drug design. Current Pharmaceutical Design 2008; 14: 1217-1224. .

Google Scholar

Robak T, Gladalska A, Stepień H, Robak E. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm 1998; 7: 347-353. .

Google Scholar

Choy EH, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002; 46: 3143-3150. .

Google Scholar

10.

Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 54: 2817-2829. .

Google Scholar

11.

Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-997. .

Google Scholar

12.

Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58: 2968-2980. .

Google Scholar

13.

Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicenter randomised placebo-controlled trial. Ann Rheum Dis 2008; 67: 1516-1523. .

Google Scholar

14.

Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 2009. Available at: doi:10.1136/ ard.2008.105197. .

Google Scholar

15.

Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x-ray reader blinded randomized controlled trial of tocilizumab. Ann Rheum Dis 2007; 66: 1162-1167. .

Google Scholar

16.

Kremer JM, Fleischmann RM, Halland A-M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate response to methotrexate: The LITHE Study. ACR/ARHP Annual Scientific Meeting, San Francisco 24-29 October 2008, Abstract L14 (LITHE). .

Google Scholar

17.

Charakterystyka Produktu Leczniczego – RoActemra. .

Google Scholar

Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Submit your paper

eISSN:	2084-9834
ISSN:	0034-6233